BIOMAT Database Logo BIOMAT Database Logo

Serological responses in cats vaccinated with FeLV ISCOM and an inactivated FeLV vaccine. 1989

A Osterhaus, and K Weijer, and F UytdeHaag, and P Knell, and O Jarrett, and L Akerblom, and B Morein
Department of Immunobiology, National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands.

Various approaches have been considered for generation of effective and safe vaccines against retroviruses, including HIV, with limited success. In the present vaccination study, encompassing 137 household cats, we have composed an experimental ISCOM subunit vaccine containing gp70 of feline leukaemia virus (FeLV)--the external glycosylated envelope protein, and the transmembrane protein p15E, with a commercial available inactivated FeLV vaccine (Leukocell). The two vaccines were estimated to contain approximately the same amount of gp70 antigen and the cats were immunized three times according to the recommendations of the commercial vaccine. A control preparation not containing gp70 or p15E was also included. During the observation period of 200 days all cats remained healthy and no virus was isolated during the isolation attempts. The serological responses were measured in ELISA, membrane immunofluorescence (MIF) and virus neutralization (VN) tests. In contrast to the cats in the other groups almost all ISCOM-vaccinated cats responded by seroconversion or increased titres in the three tests. The development of specific antibodies to gp70 and p15E were confirmed in Western blot. These results clearly illustrate the potential of the ISCOM structure for the development of safe and effective vaccines against retroviruses.

UI MeSH Term Description Entries
D007117 Immunization, Secondary Any immunization following a primary immunization and involving exposure to the same or a closely related antigen. Immunization, Booster,Revaccination,Secondary Immunization,Booster Immunization,Booster Immunizations,Immunizations, Booster,Immunizations, Secondary,Revaccinations,Secondary Immunizations
D002415 Cats The domestic cat, Felis catus, of the carnivore family FELIDAE, comprising over 30 different breeds. The domestic cat is descended primarily from the wild cat of Africa and extreme southwestern Asia. Though probably present in towns in Palestine as long ago as 7000 years, actual domestication occurred in Egypt about 4000 years ago. (From Walker's Mammals of the World, 6th ed, p801) Felis catus,Felis domesticus,Domestic Cats,Felis domestica,Felis sylvestris catus,Cat,Cat, Domestic,Cats, Domestic,Domestic Cat
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014759 Viral Envelope Proteins Integral membrane proteins that are incorporated into the VIRAL ENVELOPE. They are glycosylated during VIRAL ASSEMBLY. Envelope Proteins, Viral,Viral Envelope Glycoproteins,Viral Envelope Protein,Virus Envelope Protein,Virus Peplomer Proteins,Bovine Leukemia Virus Glycoprotein gp51,Hepatitis Virus (MHV) Glycoprotein E2,LaCrosse Virus Envelope Glycoprotein G1,Simian Sarcoma Virus Glycoprotein 70,Viral Envelope Glycoprotein gPr90 (Murine Leukemia Virus),Viral Envelope Glycoprotein gp55 (Friend Virus),Viral Envelope Proteins E1,Viral Envelope Proteins E2,Viral Envelope Proteins gp52,Viral Envelope Proteins gp70,Virus Envelope Proteins,Envelope Glycoproteins, Viral,Envelope Protein, Viral,Envelope Protein, Virus,Envelope Proteins, Virus,Glycoproteins, Viral Envelope,Peplomer Proteins, Virus,Protein, Viral Envelope,Protein, Virus Envelope,Proteins, Viral Envelope,Proteins, Virus Envelope,Proteins, Virus Peplomer
D014765 Viral Vaccines Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease. Viral Vaccine,Vaccine, Viral,Vaccines, Viral
D015151 Immunoblotting Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies. Dot Immunoblotting,Electroimmunoblotting,Immunoelectroblotting,Reverse Immunoblotting,Immunoblotting, Dot,Immunoblotting, Reverse,Dot Immunoblottings,Electroimmunoblottings,Immunoblottings,Immunoblottings, Dot,Immunoblottings, Reverse,Immunoelectroblottings,Reverse Immunoblottings
D015164 Vaccines, Inactivated Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins. Inactivated Vaccine,Killed Vaccine,Killed Vaccines,Vaccines, Killed,Inactivated Vaccines,Vaccine, Inactivated,Vaccine, Killed
D015682 Retroviridae Proteins, Oncogenic Retroviral proteins that have the ability to transform cells. They can induce sarcomas, leukemias, lymphomas, and mammary carcinomas. Not all retroviral proteins are oncogenic. Oncogenic Retroviridae Proteins,Proteins, Oncogenic Retroviridae

Related Publications

A Osterhaus, and K Weijer, and F UytdeHaag, and P Knell, and O Jarrett, and L Akerblom, and B Morein
Efficacy of an inactivated FeLV vaccine compared to a recombinant FeLV vaccine in minimum age cats following virulent FeLV challenge.
May 2014, Vaccine,
A Osterhaus, and K Weijer, and F UytdeHaag, and P Knell, and O Jarrett, and L Akerblom, and B Morein
Long-term immunity in cats vaccinated with an inactivated trivalent vaccine.
May 1999, American journal of veterinary research,
A Osterhaus, and K Weijer, and F UytdeHaag, and P Knell, and O Jarrett, and L Akerblom, and B Morein
Serological responses in pigs vaccinated with inactivated porcine parvovirus.
November 1977, Australian veterinary journal,
A Osterhaus, and K Weijer, and F UytdeHaag, and P Knell, and O Jarrett, and L Akerblom, and B Morein
Antibody response of cats vaccinated with an inactivated cell culture feline panleukopenia vaccine.
June 1972, Journal of the American Veterinary Medical Association,
A Osterhaus, and K Weijer, and F UytdeHaag, and P Knell, and O Jarrett, and L Akerblom, and B Morein
Comparing the efficacy of FeLV vaccines: comment on: Stuke, K. et al. Efficacy of an inactivated FeLV vaccine compared to a recombinant FeLV vaccine in minimum age cats following virulent FeLV challenge. Vaccine 2014;32(22):2599-603.
June 2015, Vaccine,
A Osterhaus, and K Weijer, and F UytdeHaag, and P Knell, and O Jarrett, and L Akerblom, and B Morein
Humoral responses in naive or SARS-CoV-2 experienced individuals vaccinated with an inactivated vaccine.
August 2021, Cell discovery,
A Osterhaus, and K Weijer, and F UytdeHaag, and P Knell, and O Jarrett, and L Akerblom, and B Morein
Comparison of the safety and efficacy of a recombinant feline leukemia virus (FeLV) vaccine delivered transdermally and an inactivated FeLV vaccine delivered subcutaneously.
January 2004, Veterinary therapeutics : research in applied veterinary medicine,
A Osterhaus, and K Weijer, and F UytdeHaag, and P Knell, and O Jarrett, and L Akerblom, and B Morein
Investigation of antigen specific lymphocyte responses in healthy horses vaccinated with an inactivated West Nile virus vaccine.
December 2008, Veterinary immunology and immunopathology,
A Osterhaus, and K Weijer, and F UytdeHaag, and P Knell, and O Jarrett, and L Akerblom, and B Morein
Efficacy of a nonadjuvanted recombinant FeLV vaccine and two inactivated FeLV vaccines when subject to consistent virulent FeLV challenge conditions.
September 2017, Biologicals : journal of the International Association of Biological Standardization,
A Osterhaus, and K Weijer, and F UytdeHaag, and P Knell, and O Jarrett, and L Akerblom, and B Morein
Spatial Analyses of Oral Polio Vaccine Transmission in an Community Vaccinated With Inactivated Polio Vaccine.
October 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Copied contents to your clipboard!